Ce diaporama a bien été signalé.
Nous utilisons votre profil LinkedIn et vos données d’activité pour vous proposer des publicités personnalisées et pertinentes. Vous pouvez changer vos préférences de publicités à tout moment.
PREVENTION AND TREATMENT OF
DEEP VEIN THROMBOSIS


 DeShawndre Bridley
 6th Year Doctorate of Pharmacy Candidate
 Florida ...
OBJECTIVES

 Case Presentation
 Outline DVT
     Pathophysiology

     Epidemiology

     Diagnosis

     Complicati...
CASE PRESENTATION
   M.H. is a 47 y/o, 268lb WF admitted to the ER on 10/22/07

   CC: “My calf started to swell last we...
CASE PRESENTATION

 PMH: Previous DVT at the age of 38;
  treated with warfarin for 3 months
 FH: Father died at 42 from...
CASE PRESENTATION

 SH: Patient lives with her husband and 16
  y/o son; works in a department store as a
  cashier. 24 p...
WHAT IS A DEEP VEIN THROMBOSIS?
DEEP VEIN THROMBOSIS

 Deep vein thrombosis (DVT) is the
  development of thrombi in the deep veins
  of the extremities ...
EPIDEMIOLOGY & DEMOGRAPHICS

 Annual incidence in urban population is
  1.6 cases/1000 persons.
 The risk of recurrent t...
ETIOLOGY

The etiology is often multifactorial (prolonged
 stasis, coagulation abnormalities, vessel
 wall trauma).
The fo...
ETIOLOGY
   Visceral cancer (lung, pancreas, alimentary
    tract, GU tract)
   Age >60 yr.
   History of thromboemboli...
ETIOLOGY

 Pregnancy and early puerperium
 Obesity, CHF

 Surgery requiring >30 min of anesthesia

 Gynecologic surger...
ETIOLOGY

 Recent travel (within 2 wk, lasting >6 hr)
 Smoking and abdominal obesity

 Central venous catheter or pacem...
DIAGNOSIS

 Symptoms: The patient may complain of
  leg swelling, pain, or warmth.
 Signs: The patient’s superficial vei...
DIAGNOSIS

   Diagnostic Tests
     Duplexultrasonography
     Venography (aka phlebography)
       “Gold   Standard” ...
DIAGNOSIS

   Laboratory Tests
     Serum  Concentrations of D-dimer, a by-
      product of thrombin generation, usuall...
NONPHARMACOLOGIC THERAPY

Initial bed rest for 1-4 days followed by
 gradual resumption of normal activity
 Patient educ...
ACUTE GENERAL PHARMACAOTHERAPY
 Traditional treatment consists of IV
  unfractionated heparin for 4 to 7 days
  followed ...
DOSAGES FOR LMWH AND UFH

 Enoxaparin (Lovenox) 1mg/kg every 12
  hours or 1.5mg/kg every 24 hours
 Dalteparin (Fragmin)...
ADVANTAGES OF LOW MOLECULAR WEIGHT
    HEPARIN OVER UNFRACTIONATED HEPARIN

   More reliable dose-response relation

   ...
ACUTE GENERAL PHARMACOTHERAPY

 Once-daily fondaparinux (Arixtra), a
  synthetic analog of heparin, is also as
  effectiv...
ACUTE GENERAL PHARMACOTHERAPY

 Warfarin therapy should be initiated when
  appropriate (usually within 72 hr of
  initia...
ACUTE GENERAL PHARMACOTHERAPY

   Low–molecular-weight heparin, when
    used, should be overlapped with warfarin
    for...
ACUTE GENERAL PHARMACOTHERAPY

   Exclusions from outpatient treatment of
    DVT include patients with potential high
  ...
ACUTE GENERAL PHARMACOTHERAPY

   Insertion of an inferior vena cava filter to
    prevent pulmonary embolism is
    reco...
ACUTE GENERAL PHARMACOTHERAPY
 Thrombolytic therapy (streptokinase) can
  be used in rare cases (unless
  contraindicated...
CHRONIC PHARMACOTHERAPY

 Conventional-intensity warfarin therapy is
  more effective than low-intensity warfarin
  thera...
CHRONIC PHARMACOTHERAPY
   The optimal duration of anticoagulant therapy
    varies with the cause of DVT and the patient...
CHRONIC PHARMACOTHERAPY

   Measurement of d-dimer after withdrawal
    of oral anticoagulation may be useful to
    esti...
PEARLS AND CONSIDERATIONS

   When using heparin, there is a risk of
    heparin-induced thrombocytopenia (with
    unfra...
PEARLS AND CONSIDERATIONS

   Approximately 20%-50% of patients with
    DVT develop postthrombotic syndrome
    characte...
PEARLS AND CONSIDERATIONS

   Exercise following DVT is reasonable
    because it improves flexibility of the
    affecte...
PREVENTION IS BETTER THAN TREATMENT
   Mechanical Methods
     Earlymobilization as soon as possible after
      surgery...
PEARLS AND CONSIDERATIONS
   Prophylaxis of DVT is recommended in all
    patients at risk (e.g., low–molecular-
    weig...
PEARLS AND CONSIDERATIONS

   Fondaparinux (Arixtra), a synthetic analog
    of heparin, can also be used for
    prevent...
CASE PRESENTATION
   Subjective:
       Calf pain and swelling
       Risk Factors: Smoking, SERM use, Previous DVT
  ...
CASE PRESENTATION

   Assessment:
     AcuteDeep vein thrombosis of the right
     posterior tibial vein requiring initi...
DVTs in and/or around the politeal vein are termed proximal
CASE PRESENTATION

Plan:
Treatment
 Day 1-5:
   Enoxaparin  122 U (1mg/kg) SC every 12
    hours for 5 days
   Warfarin...
CASE PRESENTATION

Plan
 Day 6
   Discontinue   LMWH
     Patientis to continue on warfarin therapy for at
     least o...
REFERENCES

1.   Anderson F.A. , Jr, Spencer F.A., Risk factors for venous
     thromboembolism. Circulation (2003) 107 : ...
QUESTIONS??
Deep Vein Thrombosis
Deep Vein Thrombosis
Prochain SlideShare
Chargement dans…5
×

sur

Deep Vein Thrombosis Slide 1 Deep Vein Thrombosis Slide 2 Deep Vein Thrombosis Slide 3 Deep Vein Thrombosis Slide 4 Deep Vein Thrombosis Slide 5 Deep Vein Thrombosis Slide 6 Deep Vein Thrombosis Slide 7 Deep Vein Thrombosis Slide 8 Deep Vein Thrombosis Slide 9 Deep Vein Thrombosis Slide 10 Deep Vein Thrombosis Slide 11 Deep Vein Thrombosis Slide 12 Deep Vein Thrombosis Slide 13 Deep Vein Thrombosis Slide 14 Deep Vein Thrombosis Slide 15 Deep Vein Thrombosis Slide 16 Deep Vein Thrombosis Slide 17 Deep Vein Thrombosis Slide 18 Deep Vein Thrombosis Slide 19 Deep Vein Thrombosis Slide 20 Deep Vein Thrombosis Slide 21 Deep Vein Thrombosis Slide 22 Deep Vein Thrombosis Slide 23 Deep Vein Thrombosis Slide 24 Deep Vein Thrombosis Slide 25 Deep Vein Thrombosis Slide 26 Deep Vein Thrombosis Slide 27 Deep Vein Thrombosis Slide 28 Deep Vein Thrombosis Slide 29 Deep Vein Thrombosis Slide 30 Deep Vein Thrombosis Slide 31 Deep Vein Thrombosis Slide 32 Deep Vein Thrombosis Slide 33 Deep Vein Thrombosis Slide 34 Deep Vein Thrombosis Slide 35 Deep Vein Thrombosis Slide 36 Deep Vein Thrombosis Slide 37 Deep Vein Thrombosis Slide 38 Deep Vein Thrombosis Slide 39 Deep Vein Thrombosis Slide 40 Deep Vein Thrombosis Slide 41 Deep Vein Thrombosis Slide 42 Deep Vein Thrombosis Slide 43
Prochain SlideShare
Anticoagulant in DVT and APE
Suivant
Télécharger pour lire hors ligne et voir en mode plein écran

5 j’aime

Partager

Télécharger pour lire hors ligne

Deep Vein Thrombosis

Télécharger pour lire hors ligne

Deep Vein Thrombosis

  1. 1. PREVENTION AND TREATMENT OF DEEP VEIN THROMBOSIS DeShawndre Bridley 6th Year Doctorate of Pharmacy Candidate Florida A&M University
  2. 2. OBJECTIVES  Case Presentation  Outline DVT  Pathophysiology  Epidemiology  Diagnosis  Complications  Discuss Pharmacological Management  Review Case Study
  3. 3. CASE PRESENTATION  M.H. is a 47 y/o, 268lb WF admitted to the ER on 10/22/07  CC: “My calf started to swell last week. Now the pain is so bad that I’m having a hard time walking.”  HPI: Noticed swelling of the right calf approximately 4 days ago. She reported to the ED of her local hospital 1 day after the onset of calf pain and swelling. Venous Dopplers were performed and the patient was told that she had a blood clot in her right leg. According to the patient she was given a prescription for an injection and instructed to follow-up with her PCP within the next 1 to 2 days. She failed to have the prescription filled because her pharmacy did not have the drug in stock. Because of increasing pain and discomfort, M.H. was seen by her physician this morning who recommended hospitalization to initialize therapy for her blood clot.
  4. 4. CASE PRESENTATION  PMH: Previous DVT at the age of 38; treated with warfarin for 3 months  FH: Father died at 42 from MI; mother alive at 71 with breast cancer diagnosed 5 years ago, s/p radiation/chemotherapy; sister alive and well. No family history of venous thromboembolic disease reported.
  5. 5. CASE PRESENTATION  SH: Patient lives with her husband and 16 y/o son; works in a department store as a cashier. 24 pack-year smoking history; currently smokes ½ to 1 ppd. (-) EtOH or IVDA  Meds: Raloxifene 60mg PO qd Multivitamin 1 tab PO qd Denies the use of herbal products
  6. 6. WHAT IS A DEEP VEIN THROMBOSIS?
  7. 7. DEEP VEIN THROMBOSIS  Deep vein thrombosis (DVT) is the development of thrombi in the deep veins of the extremities or pelvis.  DVT  Deep venous thrombophlebitis
  8. 8. EPIDEMIOLOGY & DEMOGRAPHICS  Annual incidence in urban population is 1.6 cases/1000 persons.  The risk of recurrent thromboembolism is higher among men than women  Annual incidence is 0.1% in white population
  9. 9. ETIOLOGY The etiology is often multifactorial (prolonged stasis, coagulation abnormalities, vessel wall trauma). The following are risk factors for DVT: • Prolonged immobilization (≥3 days) • Postoperative state • Trauma to pelvis and lower extremities • Birth control pills, high-dose estrogen therapy;
  10. 10. ETIOLOGY  Visceral cancer (lung, pancreas, alimentary tract, GU tract)  Age >60 yr.  History of thromboembolic disease  Hematologic disorders (e.g., antithrombin III deficiency, protein C deficiency, protein S deficiency, heparin cofactor II deficiency, sticky platelet syndrome, G20210A prothrombin mutation, lupus anticoagulant, dysfibrinogenemias, anticardiolipi n antibody, hyperhomocysteinemia, concurrent homocystinuria, high levels of factors VIII, XI, and factor V Leiden mutation)
  11. 11. ETIOLOGY  Pregnancy and early puerperium  Obesity, CHF  Surgery requiring >30 min of anesthesia  Gynecologic surgery (particularly gynecologic cancer surgery)
  12. 12. ETIOLOGY  Recent travel (within 2 wk, lasting >6 hr)  Smoking and abdominal obesity  Central venous catheter or pacemaker insertion  Superficial vein thrombosis, varicose veins
  13. 13. DIAGNOSIS  Symptoms: The patient may complain of leg swelling, pain, or warmth.  Signs: The patient’s superficial veins may be dilated, and a “palpable cord” may be felt in the affected leg. The patient may experience pain in the back of the knee when the examiner dorsiflexes the foot of the affected leg.
  14. 14. DIAGNOSIS  Diagnostic Tests  Duplexultrasonography  Venography (aka phlebography)  “Gold Standard” for DVT diagnosis
  15. 15. DIAGNOSIS  Laboratory Tests  Serum Concentrations of D-dimer, a by- product of thrombin generation, usually are elevated.  The patient may have an elevated erythrocyte sedimentation rate (ESR) and White Blood Cell (WBC) count.
  16. 16. NONPHARMACOLOGIC THERAPY Initial bed rest for 1-4 days followed by gradual resumption of normal activity  Patient education on anticoagulant therapy and associated risks
  17. 17. ACUTE GENERAL PHARMACAOTHERAPY  Traditional treatment consists of IV unfractionated heparin for 4 to 7 days followed by warfarin therapy.  Low–molecular-weight heparin enoxaparin (Lovenox) is also effective for initial management of DVT and allows outpatient treatment.  Recommended dose is 1 mg/kg q12h SC and continued for a minimum of 5 days and until a therapeutic INR (2-3) has been achieved with warfarin
  18. 18. DOSAGES FOR LMWH AND UFH  Enoxaparin (Lovenox) 1mg/kg every 12 hours or 1.5mg/kg every 24 hours  Dalteparin (Fragmin) 100units/kg every 12 hours or 200units/kg every 24 hours  Tinzaparin (Innohep) 175units/kg every 24 hours  UFH: Loading dose of 80 to 100units/kg (max. 10,000units) followed by a continuous IV infusion at an initial rate of 17 to 20 units/kg/h (max. 2300 units/h)
  19. 19. ADVANTAGES OF LOW MOLECULAR WEIGHT HEPARIN OVER UNFRACTIONATED HEPARIN  More reliable dose-response relation  No need for laboratory monitoring with the activated partial thromboplastin time (although can be monitored with anti-Xa activity)  No need for dose adjustments  Lower incidence of thrombocytopenia  No excess bleeding  Can be administered by the patient at home  Economically advantageous
  20. 20. ACUTE GENERAL PHARMACOTHERAPY  Once-daily fondaparinux (Arixtra), a synthetic analog of heparin, is also as effective and safe as twice daily enoxaparin in the initial treatment of patients with symptomatic DVT.  Selective inhibitor of factor Xa  Dose: 7.5mg SC daily
  21. 21. ACUTE GENERAL PHARMACOTHERAPY  Warfarin therapy should be initiated when appropriate (usually within 72 hr of initiation of heparin).  Interferes with vitamin K dependent factors (II, VII, IX, X)  Interactions: Ethanol, Vitamin E, Cranberry juice  Pregnancy category X
  22. 22. ACUTE GENERAL PHARMACOTHERAPY  Low–molecular-weight heparin, when used, should be overlapped with warfarin for at least 5 days and until the INR has exceeded 2 for 2 consecutive days.
  23. 23. ACUTE GENERAL PHARMACOTHERAPY  Exclusions from outpatient treatment of DVT include patients with potential high complication risk (e.g., Hemoglobin <7, platelet count <75,000, guaiac-positive stool, recent CVA or noncutaneous surgery, noncompliance).
  24. 24. ACUTE GENERAL PHARMACOTHERAPY  Insertion of an inferior vena cava filter to prevent pulmonary embolism is recommended in patients with contraindications to anticoagulation
  25. 25. ACUTE GENERAL PHARMACOTHERAPY  Thrombolytic therapy (streptokinase) can be used in rare cases (unless contraindicated) in patients with extensive iliofemoral venous thrombosis and a low risk of bleeding  Not generally used unless there is a massive thrombus or limb salvage is necessary (due to gangrene)  Has not been shown to decrease morbidity or mortality in PE
  26. 26. CHRONIC PHARMACOTHERAPY  Conventional-intensity warfarin therapy is more effective than low-intensity warfarin therapy for the long term prevention of recurrent DVT.  The low-intensity warfarin regimen does not reduce the risk of clinically important bleeding.
  27. 27. CHRONIC PHARMACOTHERAPY  The optimal duration of anticoagulant therapy varies with the cause of DVT and the patient's risk factors:  1. Therapy for 3-6 mo. is generally satisfactory in patients with reversible risk factors (low-risk group).  2. Anticoagulation for at least 6 mo. is recommended for patients with idiopathic venous thrombosis or medical risk factors for DVT (intermediate-risk group).  3. Indefinite anticoagulation is necessary in patients with DVT associated with active cancer; long-term anticoagulation is also indicated in patients with inherited thrombophilia (e.g., deficiency of protein C or S antibody), antiphospholipid, and those with recurrent episodes of idiopathic DVT (high-risk group).
  28. 28. CHRONIC PHARMACOTHERAPY  Measurement of d-dimer after withdrawal of oral anticoagulation may be useful to estimate the risk of recurrence. Patients with a first spontaneous DVT and a d- dimer level <250 μg/mL after withdrawal of oral anticoagulation have a low risk of DVT recurrence.
  29. 29. PEARLS AND CONSIDERATIONS  When using heparin, there is a risk of heparin-induced thrombocytopenia (with unfractionated more so than with LMWH). Platelet count should be obtained initially and repeated every 3 days while on heparin.
  30. 30. PEARLS AND CONSIDERATIONS  Approximately 20%-50% of patients with DVT develop postthrombotic syndrome characterized by leg edema, pain, venous ectasia, skin induration, and ulceration.
  31. 31. PEARLS AND CONSIDERATIONS  Exercise following DVT is reasonable because it improves flexibility of the affected leg and does not increase symptoms in patients with postthrombotic syndrome
  32. 32. PREVENTION IS BETTER THAN TREATMENT  Mechanical Methods  Earlymobilization as soon as possible after surgery  Graded compression stocking  Pharmacological Methods  UFH  LMWH  Fondaparinux  Warfarin
  33. 33. PEARLS AND CONSIDERATIONS  Prophylaxis of DVT is recommended in all patients at risk (e.g., low–molecular- weight heparin [enoxaparin 30 mg SC bid] after major trauma, post surgery of hip and knee; enoxaparin 40 mg SC qd post– abdominal surgery in patients with moderate to high DVT risk; gradient elastic stockings alone or in combination with intermittent pneumatic compression [IPC] boots following neurosurgery).
  34. 34. PEARLS AND CONSIDERATIONS  Fondaparinux (Arixtra), a synthetic analog of heparin, can also be used for prevention of DVT after hip fracture surgery, hip replacement, or knee replacement. Initial dose is 2.5 mg SC given 6 to 8 hr postoperatively and continued daily. Its bleeding risk is similar to enoxaparin; however, it is more effective in preventing DVT
  35. 35. CASE PRESENTATION  Subjective:  Calf pain and swelling  Risk Factors: Smoking, SERM use, Previous DVT  Objective:  (+) Homan’s sign in right calf with no palpable cord  Factor V Leiden Mutation – positive  Venous compression Ultrasonography- RLE shows non compressibility of the right posterior tibial vein with no color flow. Normal compressibility and flow demonstrated within the right common femoral and iliac veins. LLE shows normal compression of the deep venous system from the level of the common femoral vein to the popliteal vein
  36. 36. CASE PRESENTATION  Assessment:  AcuteDeep vein thrombosis of the right posterior tibial vein requiring initiation of anticoagulation. Venogram not necessary due to positive ultrasound results
  37. 37. DVTs in and/or around the politeal vein are termed proximal
  38. 38. CASE PRESENTATION Plan: Treatment  Day 1-5:  Enoxaparin 122 U (1mg/kg) SC every 12 hours for 5 days  Warfarin 5mg by mouth daily
  39. 39. CASE PRESENTATION Plan  Day 6  Discontinue LMWH  Patientis to continue on warfarin therapy for at least one year due to prior DVT
  40. 40. REFERENCES 1. Anderson F.A. , Jr, Spencer F.A., Risk factors for venous thromboembolism. Circulation (2003) 107 : pp 9-16 2. White R.H., The epidemiology of venous thromboembolism. Circulation (2003) 107 : pp I4-I8. 3. Antithrombotic Therapy for Venous Thromboembolic Disease The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest - Volume 126, Issue 3 (September 2004) 4. Barrit DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism: a controlled trial. Lancet 1960; 1:1309–1312 5. Crowther MA, Ginsberg JB, Kearon C, et al. A randomized trial comparing 5-mg and 10-mg warfarin loading doses. Arch Intern Med 1999; 159:46– 48 6. Kernohan RJ, Todd C. Heparin therapy in thromboembolic disease. Lancet 1966; 1:621–623 7. Harrison L, Johnston M, Massicotte MP, et al. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997; 126:133–136
  41. 41. QUESTIONS??
  • ssuser920f0b

    Aug. 2, 2017
  • jacob31dec

    Aug. 27, 2016
  • DrAsmaKhan

    May. 31, 2015
  • NonaAbdo

    Sep. 1, 2014
  • ilyasr2

    Aug. 9, 2014

Vues

Nombre de vues

3 798

Sur Slideshare

0

À partir des intégrations

0

Nombre d'intégrations

6

Actions

Téléchargements

152

Partages

0

Commentaires

0

Mentions J'aime

5

×